

Chapman University

## Chapman University Digital Commons

---

Pharmacy Faculty Articles and Research

School of Pharmacy

---

6-19-2020

### Targeting the Transferrin Receptor to Develop Erythropoietin for Alzheimer's Disease

Rachita K. Sumbria

Chapman University, [sumbria@chapman.edu](mailto:sumbria@chapman.edu)

Follow this and additional works at: [https://digitalcommons.chapman.edu/pharmacy\\_articles](https://digitalcommons.chapman.edu/pharmacy_articles)



Part of the [Animal Experimentation and Research Commons](#), [Medical Neurobiology Commons](#), [Nervous System Diseases Commons](#), [Other Chemicals and Drugs Commons](#), [Other Pharmacy and Pharmaceutical Sciences Commons](#), [Pharmaceutical Preparations Commons](#), and the [Therapeutics Commons](#)

---

#### Recommended Citation

Sumbria RK. Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease. *Neural Regen Res.* 2020;15(12):2251-2252. <https://doi.org/10.4103/1673-5374.284994>

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [laughtin@chapman.edu](mailto:laughtin@chapman.edu).

---

## Targeting the Transferrin Receptor to Develop Erythropoietin for Alzheimer's Disease

### Comments

This article was originally published in *Neural Regeneration Research*, volume 15, issue 12, in 2020.  
<https://doi.org/10.4103/1673-5374.284994>

### Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

### Copyright

Medknow Publications

● PERSPECTIVE

## Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease

Alzheimer's disease (AD) is the sixth leading cause of death in the United States with approximately 5.8 million Americans currently living with AD. Due to the lack of a disease modifying treatment for AD and the aging baby boomer generation, this number is projected to grow to 13.8 million by 2050 (Gaugler et al., 2019). Amyloid-beta ( $A\beta$ ) plaque accumulation, one of the major pathological hallmarks of AD, can begin > 20 years before clinical symptoms of AD. By the time AD is clinically diagnosed, neuronal loss and neuropathological lesions ( $A\beta$  plaques and tau tangles) have already occurred in many brain regions (Gaugler et al., 2019). AD dementia correlates highly with neuronal loss, and therefore, reduction of neuropathological lesions in the AD brain at the time of clinical diagnosis alone cannot reverse AD dementia. We propose that a therapy that combines a reduction of neuropathological lesions of AD along with neuronal repair and neurogenesis may be required to treat AD dementia.


Erythropoietin (EPO), a class I cytokine and growth factor, is the primary regulator of erythropoiesis and is widely used for the treatment of anemia and diseases associated with low plasma EPO (Rey et al., 2019; Sun et al., 2019a). Besides its role in hematopoiesis, the presence of EPO and its receptor in non-erythroid tissues, including the brain, suggested a role apart from its hematopoietic effects (Rey et al., 2019; Sun et al., 2019a). Today, numerous studies show the protective effects of EPO in various neurodegenerative conditions including AD (Rey et al., 2019; Sun et al., 2019a). In a recent clinical study, EPO significantly improved neuropsychological test scoring in chronic kidney disease patients with cognitive deficits (Rey et al., 2019). The mechanisms underlying neuroprotective effects of EPO in AD are pleiotropic (Sun et al., 2019a), as discussed below. In experimental AD, Lee et al. (2012) showed that EPO (5000 IU/kg per day, intraperitoneally (i.p.) for 5 days; equivalent to ~350  $\mu$ g/kg per week) reduced  $A\beta$  plaque by modulating the blood-brain barrier (BBB) influx transporter for  $A\beta$ , increased synaptophysin expression and angiogenesis in the brain, and improved contextual memory in AD transgenic mice. Similarly, Li et al. (2015) observed that EPO (1000 IU/kg per day, i.p. for 2 weeks; equivalent to ~70  $\mu$ g/kg per week) ameliorated  $A\beta_{42}$ -induced mitochondrial dysfunction, neuronal apoptosis, tau hyperphosphorylation through the regulation of glycogen synthase kinase-3 $\beta$  at multiple AD-related sites, and overall memory impairment in mice. Maurice et al. (2013) administered EPO for 4 days (125–500  $\mu$ g/kg per week, i.p.) and found a reduction in  $A\beta_{25-35}$ -induced: lipid peroxidation, Bax level, tumor necrosis factor  $\alpha$  and interleukin-1 $\beta$ , hippocampal synaptic loss and learning deficits in a non-transgenic mouse model of AD. The work by Armand-Ugon et al. (2015) showed that EPO (2500 IU/kg, 3 days a week for 4 weeks, i.p.; equivalent to ~75  $\mu$ g/kg per week) improved memory and reduced  $A\beta$  load in AD transgenic mice. Similar therapeutic effects of EPO have also been demonstrated in rat AD models wherein EPO reduced memory deficits by attenuating neuronal loss, neuroinflammation and cholinergic deficits and enhanced hippocampal neuronal proliferation (Rey et al., 2019). Overall, the protective effects of EPO include enhanced neurogenesis and angiogenesis, reduced neuroinflammation, oxidative stress and mitochondrial dysfunction, and modulation of AD-hallmark pathology ( $A\beta$  and tau phosphorylation; Sun et al., 2019a). The typical dose of EPO used to treat anemia is between 100–400 IU/kg per dose, which is, many-fold lower than the dose of EPO used in the aforementioned AD experimental studies. Large EPO doses were used in experimental AD because the large molecular weight (30.4 kDa) and polarity of EPO limit its entry into the brain across the BBB (Boado et al., 2010). This is the first obstacle to the development of EPO for a central nervous system disease including AD.

The second obstacle to the development of this neurotrophin for AD is the unwanted hematopoietic adverse effects associated with high EPO doses. This is particularly relevant while trying to develop EPO for AD due to chronicity of AD treatment and the potential for continuous EPO receptor stimulation. There have been limited studies reporting the hematopoietic effects of chronic EPO dosing in experimental AD, and a recent study showed marked elevation in hematocrit and reduction in reticulocytes with chronic EPO dosing in AD transgenic mice (Armand-Ugon et al., 2015). Alternate non-hematopoietic variants of EPO that retain neuroprotective effects have been developed and studied (Sun et al., 2019a), however we have taken a different approach to offset the two aforementioned obstacles to develop EPO for AD, which will be discussed below.

A BBB-penetrable EPO has been engineered by fusing human EPO to a chimeric monoclonal antibody against the mouse transferrin receptor (TfRMAB), and the fusion protein is designated as TfRMAB-EPO (Zhou et al., 2010). Human EPO was fused to the mouse TfRMAB since human EPO (reference: P01588) shares high (78.8%) amino acid identity with the mouse EPO (reference: P07321), binds mouse EPO receptor with high affinity and is what will be further developed for treatment in humans. Engineering a TfRMAB-EPO fusion protein offers dual advantages both of which are TfR mediated: 1) the TfRMAB domain of the fusion protein acts as a molecular Trojan horse to drive the EPO into the brain by binding to the BBB TfR and subsequent receptor mediated transcytosis, and 2) the TfRMAB domain also binds to the peripheral TfR to aid in systemic clearance of the TfRMAB-EPO fusion protein. The latter accelerates the peripheral clearance, reduces the systemic plasma exposure, and is expected to alleviate the hematopoietic adverse effects of EPO. The brain and plasma pharmacokinetics of TfRMAB-EPO show high brain uptake (2% injected dose/g brain in the mouse following intravenous dosing) and a 10-fold higher systemic clearance compared with EPO alone (Zhou et al., 2010).

Based on the above, in our recent work we investigated the effect of the BBB-penetrating TfRMAB-EPO fusion protein, in comparison with EPO, in a transgenic mouse model of AD. The overall aim was to determine if TfRMAB-EPO offers better therapeutic and hematologic indices compared with EPO alone, as would be expected based on the TfR-mediated BBB uptake and peripheral clearance of TfRMAB-EPO (Sun et al., 2019b). We treated male APP/PS1 transgenic mice (strain B6C3-Tg APP<sup>swe</sup>, PSEN1dE9, 85Dbo/Mmjax; 9.5 months of age at the start of the study), 2 days a week with either saline, TfRMAB-EPO (3 mg/kg per dose) or EPO (0.6 mg/kg per dose since the TfRMAB-EPO fusion protein is 20% EPO based on amino acid content) subcutaneously for 6 weeks (Sun et al., 2019b). Both TfRMAB-EPO and EPO significantly reduced brain  $A\beta$  load. It has been shown that EPO can reduce the expression of receptor for advanced glycation end products which is involved in the influx of  $A\beta$  into the brain, and both TfRMAB-EPO and EPO can modulate the expression of receptor for advanced glycation end products given its luminal location at the BBB. Interestingly, only the BBB-penetrating TfRMAB-EPO reduced brain  $A\beta_{1-42}$  which is the more pathologic and aggregation prone isoform of  $A\beta$ . BBB-penetrating TfRMAB-EPO also increased brain synaptophysin, a marker of synaptic function, in treated mice. EPO alone did not alter synaptophysin levels in the brain. Memory deficits in the mice correlated with synaptic function in our study, and mice treated with TfRMAB-EPO did not show impaired memory, however, mice treated with the EPO alone had significant memory impairment (Sun et al., 2019a).

With respect to the hematopoietic effects of chronic EPO dosing, we observed marked differences in the hematologic indices of the mice treated with the BBB-penetrating TfRMAB-EPO and those treated with EPO alone. AD transgenic mice treated with EPO alone had elevated red blood cell indices (hematocrit, hemoglobin and red blood cell count) following 4-week treatment. This increase in the red blood cell indices is expected given the erythropoietic effects of EPO. However, TfRMAB-EPO treated mice showed no alteration in hematocrit, hemoglobin or red blood cell count throughout the study, and this can be explained by the lower plas-



**Figure 1** Transferrin receptor (TfR) mediated brain uptake and peripheral clearance of erythropoietin (EPO) fused to a monoclonal antibody against the TfR (TFRMab). TFRMab-EPO binds to blood-brain barrier (BBB) TfR enabling BBB penetration and to peripheral TfR resulting in low plasma exposure and a favorable hematologic profile. EPO on the other hand does not cross the BBB in the absence of BBB disruption. Another suggested route of EPO entry into the brain is via the BBB EPO receptors (EPOR). This route of EPO entry into the brain is currently debated. Low EPO BBB penetration necessitates high EPO doses for central nervous system diseases increasing the potential for hematologic adverse effects, as seen in our recent study (Sun et al., 2019b). The figure was created using BioRender.com.

Taken together, the results from our recent work (Sun et al., 2019b; **Figure 1**) show that while both the BBB-penetrating TFRMab-EPO and EPO (non-BBB-penetrating) reduce total A $\beta$  load in the brains of AD transgenic mice, only the BBB-penetrating TFRMab-EPO reduced brain A $\beta_{1-42}$  and increased synaptophysin. Further, EPO significantly altered multiple hematologic indices following chronic treatment, effects that were not seen with TFRMab-EPO. These favorable therapeutic and hematologic effects of TFRMab-EPO can be attributed to the TfR-mediated BBB penetration and TfR-mediated peripheral clearance that drive the EPO into

the brain and away from the peripheral circulation.

This work has been presented at the Alzheimer's Association International Conference 2019.

This work was supported by grants from the National Institute of Health, NIA R21AG055949 and R01AG062840.

**Rachita K. Sumbria\***

Department of Biopharmaceutical Sciences, School of Pharmacy and Health Sciences, Keck Graduate Institute, Claremont; Department of Neurology, University of California, Irvine, CA, USA

\*Correspondence to: Rachita K. Sumbria, PhD, rsumbria@kgi.edu. orcid: 0000-0002-7459-0723 (Rachita K. Sumbria)

Received: January 31, 2020

Peer review started: February 17, 2020

Accepted: March 30, 2020

Published online: June 19, 2020

doi: 10.4103/1673-5374.284994

Copyright license agreement: The Copyright License Agreement has been signed by the author before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

## References

- Armand-Ugon M, Aso E, Moreno J, Riera-Codina M, Sanchez A, Vegas E, Ferrer I (2015) Memory improvement in the AbetaPP/PS1 mouse model of familial Alzheimer's disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes. *J Alzheimers Dis* 45:407-421.
- Boado RJ, Hui EK, Lu JZ, Pardridge WM (2010) Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. *J Pharmacol Exp Ther* 333:961-969.
- Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scarce-Levie K, Ernst JA, et al. (2013) Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. *Sci Transl Med* 5:183ra157.
- Gaugler J, James B, Johnson T, Marin A, Weuve J, Assoc AS (2019) 2019 Alzheimer's disease facts and figures. *Alzheimers Dement* 15:321-387.
- Lee ST, Chu K, Park JE, Jung KH, Jeon D, Lim JY, Lee SK, Kim M, Roh JK (2012) Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. *J Neurochem* 120:115-124.
- Li YP, Yang GJ, Jin L, Yang HM, Chen J, Chai GS, Wang L (2015) Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta(42) in mice. *Brain Res* 1618:159-167.
- Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, de la CG-BM, Rodriguez Cruz Y, Garcia Rodriguez JC (2013) Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) non-transgenic mouse model of Alzheimer's disease. *J Psychopharmacol* 27:1044-1057.
- Pardridge WM, Boado RJ, Patrick DJ, Ka-Wai Hui E, Lu JZ (2018) Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the Rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor. *Mol Pharm* 15:5207-5216.
- Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M, Carelli S (2019) Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases. *ASN Neuro* 11:1759091419871420.
- Sun J, Martin JM, Vanderpoel V, Sumbria RK (2019a) The promises and challenges of erythropoietin for treatment of Alzheimer's disease. *Neuromolecular Med* 21:12-24.
- Sun J, Yang J, Whitman K, Zhu C, Cribbs DH, Boado RJ, Pardridge WM, Sumbria RK (2019b) Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice. *Alzheimers Dement (N Y)* 5:627-636.
- Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM (2010) Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. *Mol Pharm* 7:2148-2155.

C-Editors: Zhao M, Li JY; T-Editor: Jia Y